SOMNF Stock Chart & Stats
$0.45
-$0.01(-6.29%)
At close: 4:00 PM EST
$0.45
-$0.01(-6.29%)
Day’s Range― - ―
52-Week Range$0.36 - $0.56
Previous CloseN/A
Volume17.00K
Average Volume (3M)0.00
Market Cap
$54.71M
Enterprise Value$102.25
Total Cash (Recent Filing)$17.18M
Total Debt (Recent Filing)$5.46M
Price to Earnings (P/E)―
Beta0.74
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,768,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)2.37
Price to Sales (P/S)0.98
P/FCF Ratio22.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$0.55Price Target Upside21.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Generation And Balance SheetImproved operating and free cash flow, combined with low leverage and $16.8m of net cash, gives SomnoMed greater flexibility to fund capacity, product development and market expansion without excessive balance-sheet risk.
Manufacturing Scale And ProductivityAdditional capacity and faster production can improve service reliability, support international growth and increase operating leverage. These capabilities may strengthen SomnoMed's position in custom devices where fulfilment speed and clinical support matter.
North America Growth And Product InnovationNorth American expansion provides a durable growth engine, while Virtus targets OSA patients with bruxism, an underserved segment. Broader clinical adoption could expand SomnoMed's addressable market and diversify regional growth.
Bears Say
Profitability Remains IncompleteAlthough gross margins and operating profitability have improved, persistent net losses show that the business has not yet converted product economics into consistent shareholder returns. This limits internally funded growth and leaves execution sensitive to cost pressures.
Structural European Reimbursement HeadwindsEurope is SomnoMed's largest region, so changes to clinical access, payer coverage and referral pathways can weigh on demand beyond a single reporting period. The resulting commercial and leadership restructure also adds execution risk.
Competitive And Adoption RisksSeveral alternative treatment and distribution models could challenge SomnoMed's differentiation, pricing and referral-based clinical workflow. If patients or providers shift toward cheaper or more convenient options, long-term market-share and margin potential may be constrained.
Somnomed Limited News
SOMNF FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest stock price was $0.36 and its highest was $0.56 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is $54.71M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,768,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in SOMNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.55 (21.63% Upside)
$0.55 (21.63% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOMNF Company Deck
SOMNF Earnings Call
Q4 2026
0:00 / 0:00
SOMNF Stock 12 Month Forecast
Average Price Target
$0.55
▲(21.63% Upside)